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Available online 2 December 2015Introduction:Direct oral anticoagulant (DOAC) intra- and inter-individual variabilitywas previously reported, but
its magnitude is still considered negligible for patient management.
Objective:To evaluate inter- and intra-individual variability in real-world atrialfibrillation patients on dabigatran,
rivaroxaban or apixaban in four Italian anticoagulation clinics and to assess the correlation between DOAC plas-
ma concentration and creatinine-clearance (CrCl).
Materials and Methods: A total of 330 consecutive patients were enrolled, of which 160 were on dabigatran (70
and 90 taking 150 mg or 110 mg twice-daily, respectively), 71 on rivaroxaban (37 and 34 taking 20 mg or
15mg once-daily) and 99 on apixaban (73 and 26 taking 5mg or 2.5 mg twice-daily). Blood was taken at trough
and peak within the first month (15–25 days) of treatment. Diluted-thrombin-time (dTT) calibrated for
dabigatran and anti-FXa calibrated for rivaroxaban or apixaban was performed.
Results:Mean inter-individual variability expressed as overall CV values for all drugs was lower at peak (CV =
46%) than at trough (CV = 63%). Mean CV% intra-individual variability was 36.6% at trough and 34.0% at peak.
Correlation with CrCl was poor for all drugs and only dabigatran at trough showed a significant correlation.
Conclusion: This multicenter study confirms high DOAC inter-individual variability that cannot be explained by
the rate of renal clearance to which the three DOACwere subjected since the correlation with CrCl was relatively
poor. This poor correlation suggests caution in using CrCl as the sole laboratory parameter to indirectly evaluate
residual circulating DOAC.
© 2015 Elsevier Ltd. All rights reserved.Keywords:
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Anticoagulation is recommended for the prevention of stroke and
systemic embolism in patients with non-valvular atrial fibrillation.
Oral drugs available for short- and long-term treatment are vitamin K
antagonists (VKA) or direct oral anticoagulants (DOAC). DOAC include
two classes of drugs that differ according to their anticoagulant mecha-
nisms: dabigatran targets thrombin, while rivaroxaban and apixaban
act specifically by inhibiting factor Xa. Phase III clinical trials showed
DOAC efficacy and safety without laboratory control and dose-is Center, AO Istituti Ospitalieri,
.adjustment. In those trials fixed doses [1–4] were used according to
clinical indications (atrial fibrillation or venous thromboembolism), pa-
tient characteristics (age, gender, body weight, concomitant adminis-
tration of potentially interfering drugs), and renal and liver function.
With this in mind it was assumed the anticoagulant effect was preva-
lently controlled by these conditions. DOAC intra- and inter-individual
variability has been previously reported [5–14], but its magnitude is
still considered negligible formanagement. Furthermore, DOAC showed
inter-individual variability of plasma concentration at steady state re-
gardless of type of drug and patient characteristic such as renal function
and bodyweight [9]. Results are however scanty and conflicting, leaving
room for further investigation.
In this study, we report results on inter-individual variability
assessed in patients with atrial fibrillation treated with dabigatran,
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clinic we also evaluated intra-individual variability by measuring the
DOAC anticoagulant effect over three consecutive time points. Finally,
we evaluated the correlation between DOAC anticoagulant levels mea-
sured with specific coagulation tests and creatinine clearance.
2. Materials and methods
2.1. Design
This is a prospective observational multicenter study in patients
with atrial fibrillation treated with DOAC and was approved by the eth-
ical committee of the general hospital of Cremona. Four large Italian
anticoagulation clinics [Bologna (A), Cremona (B), Padua (C) and Flor-
ence (D)], affiliated with the Italian Federation of Anticoagulation
Clinics (FCSA) and engaged in the Start Register (Survey on
anTicoagulated pAtients RegisTer) (www.start-register.org), were
asked to join the collaborative study by collecting plasma from patients
treated with DOAC.
2.2. Patients
After giving their informed consent, a total of 330 consecutive
patients seen at the anticoagulation clinics from Jan. 1st 2014 to
Dec. 31st 2014 were enrolled in the study providing they had been
treated with DOAC for at least one week and were available to attend
the clinic for blood sampling at the specified time points (see below).
Before starting anticoagulation, liver function was assessed by means
of liver enzymes (aspartate aminotransferase-AST and Alanine
aminotransferase-ALT). A total of 160 patients were on dabigatran (70
and 90 taking 150 mg or 110 mg twice-daily, respectively), 71 on
rivaroxaban (37 and 34 taking 20mg or 15mg once-daily, respectively),
and 99 on apixaban (73 and 26 taking 5 mg or 2.5 mg twice-daily, re-
spectively). Patients were evaluated at enrolment and the type and dos-
age of drug prescribed at the discretion of the attending physician based
on clinical characteristics. Patients were followed in the first month
(15–25 days) of treatment when trough and peak blood samples were
taken. The trough sample was obtained at 12 h from the last dose intake
for dabigatran and apixaban, and at 24 h for rivaroxaban. The peak
sample was obtained at 2 h from ingestion for all drugs and 2 h after
through sample. Concomitant food intake was ensured in patients on
rivaroxaban. Plasma samples were collected in vacuum plastic tubes
(Vacutainer, Becton Dickinson, Plymouth, UK), containing 3.2%
trisodium citrate (9:1 vol/vol, blood/anticoagulant). Blood was centri-
fuged within 1 h from collection at 2000 g for 20 min and plasma was
quickly frozen and stored at −80 °C until testing. In one clinic (B),
intra-individual variability was evaluated on 120 patients (20 patientsTable 1
Methods, analytical performances, in house intra- and inter-assay coefficient of variation (CV%
Bologna (A) Cre
Coagulometer STA compact (Stago) STA
Reagents
Dabigatran Thrombin Siemens Thr
Rivaroxaban Liquid antiXa Stago Liq
Apixaban Liquid aXa Stago Liq
Calibrators
Dabigatran Hyphen Biomed Hyp
Rivaroxaban Calibrator Stago Cal
Apixaban Calibrator Stago Cal
d-TT intra-assay CV% 2.4–5.1 2.7
dTT inter-assay CV% 1.9–7.3 3.1
Anti-FXa rivaroxaban intra-assay CV% 0.5–2.2 0.8
Anti-FXa rivaroxaban inter-assay CV% 0.6–4.4 1.0
Anti-FXa apixaban intra-assay CV% 1.3–2.4 1.1
Anti-FXa apixaban inter-assay CV% 1.7–3.6 2.0for each drug and posology) at three consecutive controls (within the
first 3 months of treatment) at trough and peak.
2.3. Laboratory tests
Diluted thrombin time (dTT) calibrated for dabigatran [15], and anti-
Xa assays calibrated for rivaroxaban or apixaban [16] were performed
locally in each clinic with appropriate coagulation platforms according
to manufacturer's indications. Methods, analytical performances, in-
house intra- and inter-assay coefficient of variation (CV%) for these
methods are in Table 1. The lower limit for dTT and for the anti-FXa is
20 ng/mL and 15 ng/mL, respectively. Results below the lower limits
were interpolated on the calibration curve from the clotting time for
dTT and from the optical density for the anti-FXa assay.
Serum creatininewasmeasured in samples taken at trough and cre-
atinine clearance calculated using the Cockroft-Gault formula for each
patient.
2.4. Statistical analysis
Inter- and intra-assay variability have been determined by calcula-
tion of themean, standarddeviation and coefficient of variation (CV) ac-
cording to CLSI recommendations (17), using internal controls at two
known drug level concentrations.
The inter-individual variability both at trough and peak was
assessed by calculating the following parameters. (i) Mean values and
range (min-max) and standard deviations (SD) for each DOAC concen-
tration measured for all the patient population. (ii) Coefficient of varia-
tion (CV%) calculated as (Mean/SD) × 100, both as the overall value (all
patients from the four clinics) and the value for each clinic. The intra-
individual variability was assessed in one clinic (clinic B) by calculating
the mean, SD and CV within each patient for whom the DOAC concen-
tration was measured at peak and trough at three time points two
weeks apart one from the other. The correlation between DOAC levels
at peak and trough vs. creatinine clearance was assessed by means of
the linear regression analysis and calculation of the r/r2 values.
3. Results
The clinical characteristics of investigated patients are in Table 2.
3.1. Inter-individual variability
The inter-individual variability expressed as CV for each drug, dos-
age and clinic is in Tables 3–5. For dabigatran 110mg, CV values ranged
from 56% to 71% at peak and from 36% to 72% at trough. For dabigatran
150mg, CV values ranged from 45% to 56% at peak and from 42% to 92%
at trough (Table 3). For apixaban 5 mg, CV values ranged from 31% to).
mona (B) Padua (C) Florence (D)
-R (Stago) CA7000 (Sysmex) ACL TOP 700 (Werfen)
ombin Stago Hyphen Hemoclot Hyphen Hemoclot
uid antiXa Stago Hyphen DiXal -
uid aXa Stago – Hyphen DiXal
hen Biomed Hyphen Biomed Hyphen Biomed
ibrator Stago Biophen Stago –
ibrator Stago – Biophen apixaban
–5.8 2.8–3.6 1.4–7.6
–7.9 4.2–8.1 3.1–6.0
–3.3 2.2–2.6 –
–4.3 2.2–6.2 –
–3.6 – 1.5–6.6
–4.5 – 2.2–6.9
Table 2
Clinical characteristics of patients.
Dabigatran
n = 160
Rivaroxaban
n = 71
Apixaban
n = 99
Age (yr) 75.4 ± 8.5 74.3 ± 6.4 76.1 ± 6.5
Weight (Kg) 75.5 ± 17.0 74.0 ± 16.5 75.5 ± 17.2
BMI (mean ± SD) 25.6 ± 6.4 25.4 ± 5.6 26.0 ± 5.5
Gender (M/F) 98/62 45/26 50/49
CHADS2 score 2.3 ± 1.0 2.4 ± 1.3 2.2 ± 1.1
Drug daily dose (n) 2 × 150 mg (70)
2 × 110 mg (90)
20 mg (37)
15 mg (34)
2 × 5 mg (73)
2 × 2.5 mg (26)
Previous stroke or TIA (n°/%) 29/18.1 12/17 18/18.2
Previous AMI (%) 6.5 14.5 15.1
Diabetes mellitus (%) 10.2 12.5 11.5
Hypertension (%) 71.5 70.8 72.1
Table 4
Mean (min–max) apixaban levels (ng/mL) determinedwith the anti-FXa assay andCV% in
patients from different clinics. The total number of observations was 198. ND, not
determined.
Apixaban
dose (mg)
Clinic Peak (ng/ml)
Mean (min–max)
CV (%) Trough(ng/ml)
Mean (min–max)
CV (%)
5 A 242 (106–374) 31 110 (44–255) 47
B 227 (102–416) 35 127 (42–283) 45
C ND ND 91 (57–196) 49
D 133 (102–164) 33 125 (92–190) 29
2.5 A 161 (109–288) 37 91 (57–196) 49
B 166 (55–300) 42 85 (38–248) 68
C ND ND ND ND
D 249 (212–287) 21 61 (26–103) 44
180 S. Testa et al. / Thrombosis Research 137 (2016) 178–18333% at peak and from 29% to 49% at trough. For apixaban 2.5 mg, CV
values ranged from 21% to 42% at peak and from 44% to 68% at trough
(Table 4). For rivaroxaban 20 mg, CV values ranged from 32% to 49%
at peak and from 40% to 103% at trough. For rivaroxaban 15 mg, CV
values ranged from 46% to 52% at peak and from 30% to 79% at trough
(Table 5). There were no major differences between the clinics.
Total inter-individual variability expressed as overall mean concen-
tration (min-max), irrespective of the clinics, is in Fig. 1. The overall
mean concentrations and ranges for all drugs were lower at trough
than at peak.
Total inter-individual variability expressed as overall CV (irrespec-
tive of clinics) is in Fig. 2. For dabigatran 110 mg, overall CV value was
69% at trough and 67% at peak. For dabigatran 150 mg, overall CV
valuewas 78% at trough and 51% at peak. For rivaroxaban 20mg, overall
CV value was 61% at trough and 43% at peak. For rivaroxaban 15 mg,
overall CV value was 60% at trough and 43% at peak. For apixaban
5 mg, overall CV value was 49% at trough and 35% at peak. For apixaban
2.5 mg, overall CV value was 59% at trough and 39% at peak. Overall CV
values for all drugs were lower at peak than at trough. Dabigatran
showed the highest overall CV value. We also calculated the percentage
of patients outside the 10° and 90° percentile to assess for the potential
of under- or over-anticoagulation. The cumulative percentage of pa-
tients outside the 10–90° percentile was 26% and 22% at trough or
peak, respectively, with negligible between-drug differences.
3.2. Intra-individual variability
Intra-individual variability, expressed as the CV value calculated for
three DOAC measured over time on 120 patients, was assessed from
the data provided by one of the clinics (clinic B), at trough and peak.
Dabigatran showed the greatest variability [CV: 59% (trough) and 60%
(peak) for the 110 mg dosage and 49% (trough), and 51% (peak) for
the 150 mg dosage]. Rivaroxaban variability was intermediate [CV:
39% (trough) and 27% (peak) for the 20 mg dosage, and 35% (trough)
and 31% (peak) for the 15 mg dosage]. Apixaban variability was the
smallest [CV: 23% (trough) and 22% (peak) for the 5 mg dosage, and
15% (trough) and 14% (peak) for the 2.5 mg dosage].Table 3
Mean (min–max) dabigatran levels (ng/mL) determined with the diluted thrombin time
and CV% in patients from different clinics. The total number of observations was 320.
Dabigatran
Dose (mg)
Clinic Peak (ng/ml)
Mean (min–max)
CV (%) Trough (ng/ml)
Mean (min–max)
CV (%)
110 A 211(31–595) 71 115(30–324) 64
B 172(38–394) 56 92(36–208) 64
C 155(50–334) 64 60(30–109) 36
D 224(46–651) 65 107(14–386) 72
150 A 187(77–427) 45 89(30–175) 42
B 191(104–435) 51 54(16–130) 70
C 222(112–447) 46 95(24–232) 52
D 240(43–538) 56 125(33–494) 923.3. Correlation of DOAC plasma concentrations vs. creatinine clearance
The r/r2 values are in Table 6. In general, there was an inverse corre-
lation between plasma DOAC concentrations and creatinine clearance.
The r/r2 values at trough were small for rivaroxaban or apixaban and
slightly higher for dabigatran.4. Discussion
DOAC inter-individual variability has been inconsistently evaluated
in published reports and guidelines, and differently commented as
being either low or high [5–14]. Furthermore, few studies investigated
all the DOAC currently licensed for treatment of patients with atrial fi-
brillation. Our multicenter study, investigating a relatively high number
of patients, shows a relatively high inter-individual variability for the
three DOAC in patients treated with different dosages. On average, the
drug concentration levels varied more than 20-times among the pa-
tients for dabigatran, nearly 15-times for rivaroxaban and 7-times for
apixaban. This variability, observed in real life patients, compares favor-
ablywith that already reported for dabigatran [11,12,18] or rivaroxaban
[11] for results stemming from the clinical trials. Variabilitywas similar-
ly high if assessedwithin each clinic or evaluated as awhole, suggesting
that it cannot be accounted for by the variability of the different labora-
tory assays. Furthermore, variabilitywas considerably higher in patients
treated with the lowest dose of DOAC. This observation may have im-
portant practical implications since on the one hand it supports the
strategy of assigning lower doses to patients with specific clinical char-
acteristics, while on the other hand it shows that the same patient may
reveal a greater variability with respect to anticoagulation, regardless of
the clinical criteria adopted to assign drug dosage. It is intriguing that
patients taking the same oral dose of single DOAC may present with
highly variable plasma concentrations. Different DOACmetabolism pat-
terns in individual patients may be the likely explanation for this vari-
ability. Our data show a greater variability at trough than at peak
levels. Although the reason for this is not known, drug absorption isTable 5
Mean (min–max) rivaroxaban levels (ng/mL) determined with the anti-factor Xa assay
and CV% in patients from different clinics. The total number of observations was 142.
ND, not determined.
Rivaroxaban
Dose (mg)
Clinic Peak (ng/ml)
Mean (min–max)
CV (%) Trough (ng/ml)
Mean (min–max)
CV (%)
20 A 247 (61–449) 49 39 (16–74) 40
B 229 (65–370) 37 41 (16–106) 67
C 231 (138–341) 32 43 (5–119) 103
D ND ND ND ND
15 A 190 (77–355) 50 25 (17–49) 32
B 229 (149–365) 52 26 (19–34) 30
C 205 (85–393) 46 32 (0–88) 79
D ND ND ND ND
Fig. 1.Distribution of DOAC plasma concentrations in treated patients. Horizontal bars representmean (middle bar) andmin–max values recorded for all patients. Numbers of patients are
within brackets.
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affected by a greater number of variables than the former [19].
A crucial role in metabolism is assigned to the kidney's ability to
clear DOAC from circulation even though this is not the onlymechanism
for elimination. Although dabigatran, rivaroxaban and apixaban show
different rates of renal excretion (nearly 80%, 35% and 27%, respective-
ly), it can expected that their plasma concentrations at steady state do
correlate with calculated creatinine clearance. No formal assessment
of this correlation has however yet been reported. Our results show
that while rivaroxaban or apixaban plasma concentrations are not cor-
related with creatinine clearance at trough, the relatively high inter-
individual dabigatran variability can only in part be accounted for by a
degree of inverse correlation between its plasma concentrations and
creatinine clearance. In line with current recommendations, patients
with creatinine clearance lower than 30 mL/min were not prescribed
dabigatran in this study. Despite this, a certain degree of inversecorrelation between dabigatran plasma concentrations and creatinine
clearance was observed, supporting the idea that circulating dabigatran
is regulated by renal function even at near-normal creatinine clearance
levels and suggesting that prescribing dabigatran to patients at the
lower end of normal range for creatinine clearance may prompt exces-
sive residual plasma concentrations. Indeed, post-hoc analysis of RE-LY
trial [17] showed that trough plasma concentrations of dabigatran were
associated far more with the relative risk of hemorrhage than with the
relative risk of ischemic stroke, suggesting that the real concern for
dabigatran might be safety rather than efficacy.
The results of our study may have practical implications for patient
management.
First, there is an urgent need to establish drug-specific cut off levels
to flag concern about the occurrence of clinical (hemorrhage or throm-
bosis) events in treated patients. It is reasonable to assume that given
the relatively high inter-individual variability, it will be difficult to set
Fig. 2. Distribution of CV values calculated from DOAC concentrations in treated patients at trough and peak. Numbers of patients are within brackets.
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tients. Information on anticoagulant levels from real world patients are
needed to increase the scanty data presently available [18].
Secondly, there is a need to establish cut off drug levels to be applied
to patients receiving treatment after stopping anticoagulation in the
event of surgery or invasive procedures. It is currently thought that
owing to the relatively short DOAC half-life, residual circulating drug
levels are reasonably low when anticoagulation is discontinued two
days before surgery, provided renal function is normal. To this end, it
is recommended renal function be assessed by measuring serum creat-
inine and calculating clearance by means of the Cockroft Gault formula.
The safety of such an assessment is based on the assumption that DOAC
plasma concentrations are correlated with creatinine clearance. Our
study shows that this assumption does not hold true, particularly for
rivaroxaban and apixaban (i.e., the anti FXa drugs that show aminor de-
pendency on renal function), and may therefore lead to misleading in-
terpretation of anticoagulant status in individual patients who may
thus be at risk of bleeding during surgery. It is our view that, instead
of proposing measurement of indirect parameters such as renal and
liver function, direct measurement of the effect of drug anticoagulation
is much safer and should be performed just before surgery or invasive
procedure. Consequently, specific tests should be available in real time
in each hospital to guide the management of patients in the different
clinical conditions. The lower limits of drug detection, in our experience
through themethods used, is associated to the nearly complete absence
of residual anticoagulant activity. While the cost incurred bymeasuring
the anticoagulant effect of DOAC is probably slightly higher than that of
measuring serum creatinine, the strategy would make patient manage-
ment much safer.
Intra-individual variability is an interesting parameter since it pro-
vides information as towhether single DOAC time-pointmeasurements
may or may not characterize individual patients. If DOAC are metabo-
lized at the same rate by individual patients, their concentrations at
steady-state should be fairly constant over time and this might beTable 6
Correlation (r value), coefficient of determination (r2) and statistical significance (p) of
DOAC plasma concentrations (at peak or trough) vs. creatinine clearance.
Drug and dose (mg) C trough (r/r2) p C peak (r/r2) p
Dabigatran 110 −0.25/0.0625 0.04 −0.12/0.014 ns
Dabigatran 150 −0.32/0.1024 0.03 −0.18/0.0324 ns
Rivaroxaban 20 −0.18/0.0324 ns −0.15/0.0225 ns
Rivaroxaban 15 −0.09/0.0081 ns 0.07/0.0049 ns
Apixaban 5 −0.03/0.0009 ns −0.17/0.0289 ns
Apixaban 2.5 −0.02/0.0004 ns −0.01/0.0001 nstaken as a characteristic feature for each patient. As shown by our
study and elsewhere in the literature [12] this does not hold true for
dabigatran where intra-individual variability is considerably higher
(average CV, 55%). Rivaroxaban and apixaban showed, respectively, in-
termediate (average CV, 33%) and relatively small (average CV, 19%)
variability. Accordingly, single DOAC measurement can hardly provide
an estimation of the average anticoagulation achieved in individual pa-
tients. It should be realized that estimating the average anticoagulation
achieved with DOAC is difficult as it depends on the adsorption, me-
tabolism and clearance of the drug that may vary over time. Howev-
er, it can be assumed that when DOAC measurement is performed
after drug discontinuation and soon before surgery or invasive pro-
cedures even a single DOAC measurement may be useful to see
whether there are still excess circulating levels that may increase
the risk of bleeding.
In conclusion, this collaborative study involving four large Italian
anticoagulation clinics shows that the inter-individual variability of
plasma concentrations estimated in a relatively large number of pa-
tients with atrial fibrillation is relatively high for the three DOAC:
dabigatran (average CV= 66%), rivaroxaban (CV= 52%) and apixaban
(CV = 46%). The relatively high inter-individual variability cannot be
accounted for by the rate of renal clearance the three DOAC are
(although to a different extent) subjected to since the correlation of
their plasma concentrations and creatinine clearance was relatively
poor. The possible influence on this poor correlation brought about by
the hepatic function and other confounding variables such as gender
and body mass index has not been formally assessed. However, owing
to the real nature of this study, investigating relatively large numbers
of patients, it is unlikely that the above effects (if any) can affect the con-
clusion that the poor observed correlation argues against using creati-
nine clearance as the sole laboratory parameter to assess whether or
not residual circulating DOAC is sufficiently low to ensure low risk of
bleeding during surgery and/or invasive procedures. Intra-individual
variability is also relatively high for dabigatran, suggesting that single
DOAC measurement cannot be used to estimate the level of
anticoagulation reached at the steady-state in treated patients. All in
all, the above observations may have important practical implications
for the management of patients treated with DOAC.
Addendum
ST and AT conceived the study, reviewed the data and wrote the
manuscript. CL, VP, RA, CD, PC, LS, RP, OP, DP enrolled patients and su-
pervised laboratory measurement. ST, CD and OP analyzed the data.
GP and all the authors revised and accepted the final version of the
manuscript.
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